Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Tofacitinib Blocks Entheseal Lymphocyte Activation and Modulates MSC Adipogenesis but Does Not Directly Affect Chondro- and Osteogenesis

Tobias Russell
ORCID logo ,
Hannah Rowe
,
Charlie Bridgewood
ORCID logo ,
Richard Cuthbert
,
Abdulla Watad
ORCID logo ,
Darren Newton
,
Elena Jones
,
Dennis McGonagle
*
Version 1 : Received: 16 July 2021 / Approved: 21 July 2021 / Online: 21 July 2021 (14:38:32 CEST)
Version 2 : Received: 17 September 2021 / Approved: 21 September 2021 / Online: 21 September 2021 (14:36:07 CEST)
Version 3 : Received: 8 October 2021 / Approved: 12 October 2021 / Online: 12 October 2021 (20:39:00 CEST)

How to cite: Russell, T.; Rowe, H.; Bridgewood, C.; Cuthbert, R.; Watad, A.; Newton, D.; Jones, E.; McGonagle, D. Tofacitinib Blocks Entheseal Lymphocyte Activation and Modulates MSC Adipogenesis but Does Not Directly Affect Chondro- and Osteogenesis. Preprints 2021, 2021070494. https://doi.org/10.20944/preprints202107.0494.v1 Russell, T.; Rowe, H.; Bridgewood, C.; Cuthbert, R.; Watad, A.; Newton, D.; Jones, E.; McGonagle, D. Tofacitinib Blocks Entheseal Lymphocyte Activation and Modulates MSC Adipogenesis but Does Not Directly Affect Chondro- and Osteogenesis. Preprints 2021, 2021070494. https://doi.org/10.20944/preprints202107.0494.v1

Abstract

Entheseal spinal inflammation and new bone formation with progressive ankylosis may occur in ankylosing spondylitis (AS) and psoriatic arthritis (PsA). This study evaluated whether JAK inhibition with tofacitinib modulated the key SpA associated cytokines, TNF and IL-17A and whether tofacitinib also modulated bone marrow stromal cell-derived mesenchymal stem cells (MSCs) function including osteogenesis since post inflammation new bone formation occurs in these conditions. Methods: Conventional entheseal derived αβ CD4+ and CD8+ T-cells were in-vestigated following anti-CD3/CD28 bead stimulation to determine IL-17A and TNF levels in Tofacitinib treated (1000nM) peri-entheseal bone (PEB) and peripheral blood mononucleated cells (PBMC) following ELISA. Bone marrow stromal cell-derived mesenchymal stem cells (MSCs) colony forming unit (CFU-F) and multilineage potential was evaluated using tofacitinib (dosages ranging between 100, 500, 1000 and 10000nM). Results: Induced IL-17A and TNF cy-tokine production from both entheseal CD4+ T-cells and CD8+ T-cells were effectively inhibited by tofacitinib. Tofacitinib treatment did not impact on CFU-F potential or in vitro chondro- and osteogenesis. However, tofacitinib stimulation increased MSC adipogenic potential with greater Oil Red O stained area. Conclusion: Inducible IL-17A and TNF production by healthy human entheseal CD4+ and CD8+ T-cells was robustly inhibited in vitro by tofacitinib. However, tofa-citinib did not impact on MSC osteogenesis but stimulated in vitro MSC adipogenesis the relevance of which needs further evaluation given the adipocytes are associated with new bone formation in SpA

Keywords

Tofacitinib; JAK-STAT; chondrogenesis

Subject

Biology and Life Sciences, Biochemistry and Molecular Biology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.